[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100463680":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":10,"locations":24,"responsibleParty":90,"collaborators":10,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":94,"sex":100,"minAge":101,"maxAge":10,"enrollmentInfo":102,"targetDuration":10,"studyType":105,"phases":10,"briefSummary":106,"conditions":107,"keywords":10,"overallStatus":109,"whyStopped":10,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Novo Nordisk A\u002FS","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with Type 2 Diabetes (T2D)",null,"Selected for inclusion in the study by their primary or secondary care physicians",[13],"Other: No treatment given",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","No treatment given","The clinical management and prescribed treatment of diabetes and eASCVD\u002FASCVD risk factors are independent of this study and are part of the routine clinical practice at the discretion of the treating physician.",[9],[21],{"name":22,"affiliation":5,"role":23},"Clinical Transparency (dept. 2834)","STUDY_DIRECTOR",[25,36,45,54,63,72,81],{"facility":26,"status":10,"city":27,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":10},"Novo Nordisk Investigational Site","Manama","Bahrain","BH",{"type":31,"coordinates":32},"Point",[33,34],50.58565,26.22787,{"lat":34,"lon":33},{"facility":26,"status":10,"city":37,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":44,"contacts":10},"Alexandria","Egypt","EG",{"type":31,"coordinates":41},[42,43],29.91582,31.20176,{"lat":43,"lon":42},{"facility":26,"status":10,"city":46,"state":10,"zip":10,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":53,"contacts":10},"Amman","Jordan","JO",{"type":31,"coordinates":50},[51,52],35.94503,31.95522,{"lat":52,"lon":51},{"facility":26,"status":10,"city":55,"state":10,"zip":10,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":62,"contacts":10},"As Sālimīyah","Kuwait","KW",{"type":31,"coordinates":59},[60,61],48.07611,29.33389,{"lat":61,"lon":60},{"facility":26,"status":10,"city":64,"state":10,"zip":10,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":71,"contacts":10},"Doha","Qatar","QA",{"type":31,"coordinates":68},[69,70],51.53096,25.28545,{"lat":70,"lon":69},{"facility":26,"status":10,"city":73,"state":10,"zip":10,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":80,"contacts":10},"Johannesburg","South Africa","ZA",{"type":31,"coordinates":77},[78,79],28.04363,-26.20227,{"lat":79,"lon":78},{"facility":26,"status":10,"city":82,"state":10,"zip":10,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":89,"contacts":10},"Abu Dhabi","United Arab Emirates","AE",{"type":31,"coordinates":86},[87,88],54.39696,24.45118,{"lat":88,"lon":87},{"type":91,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100463680","an-international-chart-review-and-survey-for-the-prevalence-and-clinical-management-of-atherosclerotic-cardiovascular-diseases-in-patients-with-type-2-diabetes-across-countries-in-the-middle-east-and-africa-100463680",false,"NCT05317845","An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa","A Multi-center, Cross-sectional Chart Review and Survey to Capture the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa","PACT-MEA","Inclusion Criteria:\n\n1. Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).\n2. Male or female, age greater than or equal to 18 years at the time of signing informed consent.\n3. Diagnosed with T2D grater than or equal to 180 days prior to the day of signing informed consent\n\nExclusion Criteria:\n\n1. Previous participation in this study. Participation is defined as having given informed consent in this study.\n2. Mental incapacity, unwillingness, inability, or language barriers precluding adequate understanding or cooperation\n3. Diagnosed with Type 1 Diabetes (T1D).\n4. Patients with known congenital heart disease\u002Fmalformation","ALL","18 Years",{"count":103,"type":104},4089,"ACTUAL","OBSERVATIONAL","The study is intended to estimate the proportion and clinical management of people with type 2 diabetes having atherosclerotic cardiovascular diseases or who are at high risk to develop atherosclerotic cardiovascular diseases.\n\nParticipants will be asked to give information about their health. Partipants will continue normal way of life and will not get any medication other than those prescribed to them by the doctor.\n\nThe study will last for about 6 months.",[108],"Diabetes Mellitus, Type 2","COMPLETED","2023-03-24",{"date":112,"type":104},"2023-03-28",{"date":114,"type":104},"2022-04-21",{"date":116,"type":104},"2022-08-31",{"name":5,"class":6},7]